Lucid Diligence Brief: ERS Genomics and Aurigene CRISPR/Cas9 License
Lucid Diligence Brief: ERS Genomics’ CRISPR/Cas9 IP license to Aurigene raises…
Lucid Diligence Brief: Transcenta x EirGenix HiCB licensing
Lucid Diligence Brief: Transcenta x EirGenix HiCB licensing Professional…
Lucid Diligence Brief: Made Scientific and Cellergy Therapeutics manufacturing partnership to advance CLG-001
Lucid Diligence Brief: Made Scientific and Cellergy Therapeutics manufacturing…
